Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  RaySearch Laboratories AB (publ)    RAY B   SE0000135485

RAYSEARCH LABORATORIES AB (PUBL)

(RAY B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

RaySearch Laboratories publ : and TAE Life Sciences announce agreement on RayStation support for the Alphabeam System for BNCT

share with twitter share with LinkedIn share with facebook
07/15/2020 | 04:52am EDT

RaySearch Laboratories AB (publ) has entered into a licensing and distribution agreement with TAE Life Sciences, manufacturer of the Alphabeam™ System for boron neutron capture therapy (BNCT).

[image]

BNCT is a biologically targeted radiation therapy that kills cancer at the cellular level. The technique uses a two-step process. In the first step, patients are injected with a tumor-targeting drug that contains non-toxic and non-radioactive boron-10. In the second step, the target area is exposed to low-energy neutrons. When the boron-10 and neutrons interact, short-range,  high-energy charged particles are emitted that systemically destroy tumor cells - with minimal damage to adjacent healthy tissue and low risk of side effects. BNCT is therefore an attractive treatment modality for complicated and recurrent cancers, such as glioblastomas or head and neck cancers.

The combination of worldwide clinical interest in BNCT, advanced boron agents, modern accelerator-based neutron production technology and innovative software is paving the way for a new era in BNCT to help the fight against cancer.

The RayStation treatment planning system supports BNCT treatment planning with tools for contouring, image importing, reporting, plan creation and evaluation, as well as support for defining BNCT-specific models of relative biological effectiveness. Under the agreement, RayStation will work in conjunction with TAE Life Sciences' proprietary dose calculation software for the Alphabeam System, which can be configured for single- or multi-room BNCT centers.

Bruce Bauer, CEO, TAE Life Sciences, says: "The new era of accelerator-based BNCT offers a highly promising therapy for hard-to-treat cancers, both in effectiveness and reduced treatment time. We are excited to partner with RaySearch on the integration of RayStation with our compact Alphabeam System. Our partnership will help accelerate the commercialization of hospital-based BNCT and greatly benefit clinicians and cancer patients globally."

Johan Löf, founder and CEO, RaySearch, says: "BNCT is gaining ground as an option for certain types of tumor, and we are keen to support partner companies operating in this field of radiation therapy.  I am pleased to share the news of our partnership with TAE Life Sciences to advance cancer treatment."

For further information, please contact:
Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
johan.lof@raysearchlabs.com

Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59
peter.thysell@raysearchlabs.com

About TAE Life Sciences
TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy, accelerator-based neutron source - optimized for an in-hospital BNCT program that will one day treat patients with the most aggressive and recurrent cancers. TLS has assembled a world-class cross-functional team of clinicians, radiation oncologists, physicists and other researchers to bring its technology to the cancer patients who need it most. TLS's drug and device are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at www.taelifesciences.com

About RaySearch
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets worldwide its treatment planning system RayStation and next-generation oncology information system RayCare. Over 2,600 clinics in more than 65 countries use RaySearch software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003. More information about RaySearch is available at www.raysearchlabs.com

About RayStation
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare, the next-generation oncology information system. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.

* Subject to regulatory clearance in some markets.

This order was received in Q2/2020.

https://news.cision.com/raysearch-laboratories/r/raysearch-and-tae-life-sciences-announce-agreement-on-raystation-support-for-the-alphabeam-system-fo,c3153991

https://mb.cision.com/Main/1102/3153991/1279510.pdf

https://news.cision.com/raysearch-laboratories/i/taelifesciences-pressrelease-2,c2806246

(c) 2020 Cision. All rights reserved., source Press Releases - English


share with twitter share with LinkedIn share with facebook
All news about RAYSEARCH LABORATORIES AB (PUBL)
09/16RAYSEARCH LABORATORIES : Cutting-edge cancer treatment comes to Belgium with the..
AQ
08/28RAYSEARCH LABORATORIES : RayStation in clinical use at both of Spain's proton ce..
AQ
08/26RAYSEARCH LABORATORIES : Interim report January 1 - June 30, 2020
AQ
07/15RAYSEARCH LABORATORIES PUBL : and TAE Life Sciences announce agreement on RaySta..
AQ
07/09RAYSEARCH LABORATORIES PUBL : Further clinical implementation of deep learning s..
AQ
06/30RAYSEARCH LABORATORIES PUBL : Bulletin from the Annual General Meeting 2020
AQ
06/29RAYSEARCH LABORATORIES PUBL : Machine learning algorithm from RaySearch enhances..
AQ
06/29RAYSEARCH LABORATORIES PUBL : Pioneering oncology information system RayCare 4A ..
AQ
06/24RAYSEARCH LABORATORIES PUBL : Axim Nuclear & Oncology to supply RaySearch system..
AQ
06/24RAYSEARCH LABORATORIES PUBL : Three North African cancer centers place orders fo..
AQ
More news
Financials
Sales 2020 779 M 88,5 M 88,5 M
Net income 2020 66,5 M 7,56 M 7,56 M
Net cash 2020 15,0 M 1,70 M 1,70 M
P/E ratio 2020 41,9x
Yield 2020 0,37%
Capitalization 2 773 M 315 M 315 M
EV / Sales 2020 3,54x
EV / Sales 2021 3,01x
Nbr of Employees 396
Free-Float 69,7%
Chart RAYSEARCH LABORATORIES AB (PUBL)
Duration : Period :
RaySearch Laboratories AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RAYSEARCH LABORATORIES AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 93,50 SEK
Last Close Price 80,90 SEK
Spread / Highest target 17,4%
Spread / Average Target 15,6%
Spread / Lowest Target 13,7%
EPS Revisions
Managers
NameTitle
Johan Löf President, Chief Executive Officer & Director
Lars Micael Wollung Chairman
Peter Thysell Chief Financial Officer
Kjell Eriksson Chief Research Officer
Carl Filip Bergendal Director
Sector and Competitors
1st jan.Capitalization (M$)
RAYSEARCH LABORATORIES AB (PUBL)-24.53%315
VEEVA SYSTEMS INC.114.84%45 578
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED126.67%35 383
OMNICELL, INC.-2.59%3 404
SECTRA AB (PUBL)61.76%2 765
B-SOFT CO.,LTD.23.08%2 608